This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

LUX-Lung 3 clinical data1
GIOTRIF® (afatinib) demonstrated superior 1st-line PFS versus pemetrexed/cisplatin independent of EGFR mutational subgroup1

LUX-Lung 3 (del19/L858R): PFS by independent review (primary endpoint)

LUX-Lung 3 (del19/L858R): PFS by independent review (primary endpoint)

  • In patients with common mutations, median PFS was 13.6 and 6.9 months for GIOTRIF® (afatinib) and pemetrexed/cisplatin, respectively (HR=0.47; 95% CI, 0.34–0.65; P<0.001)1
  • 42% reduction in relative risk of death or tumour progression in the ITT population (HR=0.58; P<0.001)1

CI=confidence interval; EGFR M+=epidermal growth factor receptor mutation positive; HR=hazard ratio; ITT=intention-to-treat; PFS=progression-free survival.

LUX-Lung 6 clinical data2
GIOTRIF® (afatinib) demonstrated superior 1st-line PFS versus gemcitabine/cisplatin, consistent across all subgroups, including mutation type2

LUX-Lung 6: PFS by independent review (primary endpoint)

LUX-Lung 6: PFS by independent review (primary endpoint)

  •  72% reduction in relative risk of death or tumour progression in the GIOTRIF® (afatinib) group (HR=0.28; P<0.0001)2

CI=confidence interval; EGFR M+=epidermal growth factor receptor mutation positive; HR=hazard ratio; ITT=intention-to-treat; PFS=progression-free survival.

Watch Vera Hirsh on afatinib treatment of del19 and exon21 patients!

This video is about Vera Hirsh talking about afatinib treatment.

You may be interested in: 

Prof. Thomas J. Lynch talks about the LUX-Lung 3 results


Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist et al., Journal of Clinical Oncology 2013; 31(27):3327-34

Download the publication!

Is this information compelling to you?

Request contact
from Boehringer Ingelheim

References

  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.
  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.
  4. Paz-Arez L et al. Ann Oncol.2017; doi : 10.1093/annonc/mdw611.
  5. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.
  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.

  12. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top